caa a22 4500 465761615 CHVBK 20180323111900.0 cr unu---uuuuu 170327e19900301xx s 000 0 eng 10.1007/BF03000484 doi (NATIONALLICENCE)springer-10.1007/BF03000484 BjÖrkholm Magnus Department of Medicine, Division of Hematology, Karolinska Hospital, S-104 01, Stockholm, Sweden aut Etoposide and teniposide in the treatment of acute leukemia [Elektronische Daten] [Magnus BjÖrkholm] Etoposide and teniposide are semi-synthetic glucoside derivatives of podophyilotoxin with a documented antitumour activity in various types of malignant diseases. It was an early observation that these epiphodophyllotoxins were efficacious in hematological malignancies such as lymphomas and leukernias. In this report the clinical evidence supporting the activity of etoposide and teniposide in acute lymphoblastic (ALL) and nonlymphoblastic leukemia (ANLL) is reviewed. Unlike podophyilotoxin, etoposide and teniposide do not appear to affect microtubular function nor arrest cells in mitosis. These epiphodophyllotoxins, like other DNA intercalating agents, have topoisomerase II as their target. Most studies with etoposide have been performed in ANLL and with teniposide in ALL. This choice seems to be rather arbitrary and is better explained by traditional reasons than actual study results. The data in acute leukemias are partly flawed by the absence of certain prospective comparative trials. However, the current information on etoposide clearly shows that this agent has substantial activity in ANLL and may well be incorporated into front-line regimens and the same is true for teniposide in the treatment of ALL. Nevertheless, based on available literature, there are no convincing data to the author's mind to support that one of these agents is superior to the other in the treatment of acute leukemias. Humana Press Inc., 1990 Etoposide nationallicence Teniposide nationallicence Acute non-lymphoblastic leukemia nationallicence Acute lymphoblastic leukemia nationallicence Medical Oncology and Tumor Pharmacotherapy Humana Press 7/1(1990-03-01), 3-10 0736-0118 7:1<3 1990 7 12032 https://doi.org/10.1007/BF03000484 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF03000484 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- BjÖrkholm Magnus Department of Medicine, Division of Hematology, Karolinska Hospital, S-104 01, Stockholm, Sweden aut NATIONALLICENCE 773 0- Medical Oncology and Tumor Pharmacotherapy Humana Press 7/1(1990-03-01), 3-10 0736-0118 7:1<3 1990 7 12032 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer